Natixis Advisors LLC Has $21.14 Million Stake in Bruker Co. (NASDAQ:BRKR)

Natixis Advisors LLC increased its stake in shares of Bruker Co. (NASDAQ:BRKR) by 145.8% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 360,631 shares of the medical research company’s stock after acquiring an additional 213,937 shares during the period. Natixis Advisors LLC’s holdings in Bruker were worth $21,140,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also made changes to their positions in the company. FMR LLC grew its position in Bruker by 21.4% in the third quarter. FMR LLC now owns 14,306,122 shares of the medical research company’s stock valued at $987,981,000 after purchasing an additional 2,521,904 shares in the last quarter. Vaughan Nelson Investment Management L.P. grew its position in Bruker by 140.3% in the fourth quarter. Vaughan Nelson Investment Management L.P. now owns 1,141,762 shares of the medical research company’s stock valued at $66,930,000 after purchasing an additional 666,617 shares in the last quarter. Point72 DIFC Ltd grew its position in Bruker by 4,875.9% in the third quarter. Point72 DIFC Ltd now owns 470,171 shares of the medical research company’s stock valued at $32,470,000 after purchasing an additional 460,722 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank grew its position in Bruker by 1,933.2% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 410,234 shares of the medical research company’s stock valued at $28,331,000 after purchasing an additional 390,057 shares in the last quarter. Finally, State Street Corp grew its position in Bruker by 9.6% in the third quarter. State Street Corp now owns 3,627,300 shares of the medical research company’s stock valued at $250,501,000 after purchasing an additional 318,808 shares in the last quarter. 79.52% of the stock is currently owned by institutional investors and hedge funds.

Bruker Stock Performance

Shares of BRKR stock opened at $46.94 on Tuesday. The company has a market capitalization of $7.12 billion, a price-to-earnings ratio of 61.76, a PEG ratio of 2.16 and a beta of 1.18. The company has a debt-to-equity ratio of 1.15, a quick ratio of 0.77 and a current ratio of 1.60. The company has a 50-day simple moving average of $53.38 and a 200 day simple moving average of $58.22. Bruker Co. has a 52 week low of $44.11 and a 52 week high of $94.86.

Bruker (NASDAQ:BRKR) last announced its earnings results on Thursday, February 13th. The medical research company reported $0.76 EPS for the quarter, topping the consensus estimate of $0.75 by $0.01. Bruker had a net margin of 3.36% and a return on equity of 21.01%. On average, sell-side analysts predict that Bruker Co. will post 2.69 earnings per share for the current year.

Bruker Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, March 28th. Investors of record on Monday, March 17th will be issued a dividend of $0.05 per share. This represents a $0.20 annualized dividend and a dividend yield of 0.43%. The ex-dividend date is Monday, March 17th. Bruker’s payout ratio is 26.32%.

Wall Street Analysts Forecast Growth

A number of research analysts recently weighed in on BRKR shares. Stifel Nicolaus decreased their target price on shares of Bruker from $70.00 to $57.00 and set a “hold” rating for the company in a research report on Friday, February 14th. UBS Group began coverage on shares of Bruker in a research report on Tuesday, December 10th. They issued a “neutral” rating and a $66.00 target price for the company. Bank of America lifted their price objective on shares of Bruker from $78.00 to $80.00 and gave the company a “buy” rating in a research report on Friday, December 13th. Guggenheim reissued a “buy” rating on shares of Bruker in a research report on Monday, February 24th. Finally, The Goldman Sachs Group raised shares of Bruker from a “sell” rating to a “neutral” rating and set a $60.00 price objective for the company in a research report on Thursday, December 5th. Six investment analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $70.50.

About Bruker

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.